Publications by authors named "M Bellido"
Aim: This randomized clinical trial assessed the outcomes of nonsurgical root canal treatment (RCT), comparing a calcium silicate-based sealer (CSBS) with the single-cone technique (SC) with a zinc oxide-eugenol (ZOE) sealer and warm vertical compaction (WVC).
Methodology: Ninety-two single- and multi-rooted teeth were divided into two groups and treated using either the SC with BioRoot™ RCS (BIO) or WVC with Pulp Canal Sealer™ EWT (PCS). Teeth with apical periodontitis (AP) in both groups were further divided into BIOAP and PCSAP subgroups.
Article Synopsis
- The GAIA/CLL13 trial found that venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib combinations led to better undetectable measurable residual disease (MRD) rates and longer progression-free survival compared to traditional chemoimmunotherapy for untreated chronic lymphocytic leukaemia (CLL) patients.
- The trial was a phase 3 study involving 159 sites across Europe and the Middle East, enrolling patients aged 18 and older with specific health criteria and assigning them to different treatment groups, including standard chemoimmunotherapy and various venetoclax-based combinations.
- All treatment regimens were administered in cycles, with detailed protocols for each group, specifically focusing on
Allogeneic stem cell transplantation (alloSCT) offers curative potential for older patients with myeloid malignancies. We evaluated the efficacy and safety of alloSCT using post-transplantation cyclophosphamide (PTCy) in combination with a very short duration of immune suppression (IS) in this population. We retrospectively analyzed 92 consecutive patients aged 65 years and older who underwent an alloSCT for myeloid malignancies between February 2018 and December 2022 at our institution.
View Article and Find Full Text PDFBackground: We recently reported results of the prospective, open-label HOVON-100 trial in 334 adult patients with acute lymphoblastic leukemia (ALL) randomized to first-line treatment with or without clofarabine (CLO). No improvement of event-free survival (EFS) was observed, while a higher proportion of patients receiving CLO obtained minimal residual disease (MRD) negativity.
Aim: In order to investigate the effects of CLO in more depth, two multi-state models were developed to identify why CLO did not show a long-term survival benefit despite more MRD-negativity.